SmartCelleTM – A New Platform for Pan-Ocular Delivery
SmartCelle for Pan-Ocular Delivery
The small size (30nm) and neutral charge of SmartCelle micelles enables increased access of TA-A001 and other TALLC drugs to the cornea, the trabecular network, the anterior chamber and the posterior chamber. Passage through the aqueous channels of the sclera also allows access to the retinal pigment epithelium (RPE) and inner retinal layer. TA-A001 is not an efflux pump substrate.
Safety and Tolerability
SmartCelle micelles are well tolerated after repeated instillation or intravenous administration at high concentration. Their low molecular weight and biodegradability allows predominantly renal clearance.
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020